An improved reverse genetics system for influenza A virus generation and its implications for vaccine production.

The generation of vaccines for highly pathogenic avian influenza viruses, including those of the H5N1 subtype, relies on reverse genetics, which allows the production of influenza viruses from cloned cDNA. In the future, reverse genetics will likely be the method of choice for the generation of conventional influenza vaccine strains because gene reassortment by more traditional methods is cumbersome. Established systems for the artificial generation of influenza A viruses require transfection of cells with the eight to 12 plasmids that provide the eight influenza viral RNAs as well as the polymerase and nucleoproteins of the virus. However, cell lines appropriate for human vaccine production (e.g., Vero cells) cannot be transfected with high efficiencies. To overcome these problems, we established a reverse genetics system in which the eight RNA polymerase I transcription cassettes for viral RNA synthesis are combined on one plasmid. Similarly, two cassettes encoding the hemagglutinin and neuraminidase segments and six cassettes encoding the remaining proteins were combined. We also combined three RNA polymerase II transcription cassettes for the expression of the polymerase subunits. By combining these cassettes, we reduced the number of plasmids required for virus generation significantly and produced influenza A virus in Vero cells with higher efficiency than with the traditional 12 plasmid system. This new system is thus suitable for influenza virus vaccine production and may be applicable to other reverse genetics systems that rely on the introduction of several plasmids into eukaryotic cells.

[1]  J. Wood,et al.  Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. , 2005, Vaccine.

[2]  J. Wood,et al.  From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza , 2004, Nature Reviews Microbiology.

[3]  A. Osterhaus,et al.  For Personal Use. Only Reproduce with Permission from the Lancet , 2022 .

[4]  J. Peiris,et al.  Re-emergence of fatal human influenza A subtype H5N1 disease , 2004, The Lancet.

[5]  R. Webster,et al.  Generation of High-Yielding Influenza A Viruses in African Green Monkey Kidney (Vero) Cells by Reverse Genetics , 2004, Journal of Virology.

[6]  Marion Koopmans,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Gerdil The annual production cycle for influenza vaccine. , 2003, Vaccine.

[8]  N. Cox,et al.  Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. , 2003, Virology.

[9]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[10]  H. Mizokami,et al.  Development of Vero cell-derived inactivated Japanese encephalitis vaccine. , 2002, Biologicals : journal of the International Association of Biological Standardization.

[11]  R. Webster,et al.  Rescue of influenza B virus from eight plasmids , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Treanor,et al.  Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. , 2002, Vaccine.

[13]  Shinji Watanabe,et al.  Reverse Genetics Demonstrates that Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Essential for Replication in Cell Culture , 2002, Journal of Virology.

[14]  F. Dorner,et al.  Humoral and cell-mediated immunity to vero cell-derived influenza vaccine. , 2000, Vaccine.

[15]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. García-Sastre,et al.  Rescue of influenza A virus from recombinant DNA. , 2007, Journal of virology.

[17]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Dorner,et al.  A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production. , 1999, Wiener klinische Wochenschrift.

[19]  J. Saluzzo,et al.  Experience with vero cells at Pasteur Mérieux Connaught. , 1999, Developments in biological standardization.

[20]  A. Palache,et al.  Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. , 1999, Developments in biological standardization.

[21]  F. Dorner,et al.  Development of a Vero cell-derived influenza whole virus vaccine. , 1999, Developments in biological standardization.

[22]  P. van Ewijk,et al.  Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. , 1999, Developments in biological standardization.

[23]  Y. Guan,et al.  Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. , 1998, Virology.

[24]  F. Dorner,et al.  Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. , 1998, Vaccine.

[25]  R. Webster,et al.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.

[26]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[27]  Y. Kawaoka,et al.  Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus , 1994, Journal of virology.

[28]  O. Elroy-Stein,et al.  New mammalian expression vectors , 1990, Nature.